ATE374829T1 - Herpesvirusvektoren für dendritische zellen - Google Patents

Herpesvirusvektoren für dendritische zellen

Info

Publication number: ATE374829T1
Authority: AT; Austria
Prior art keywords: herpes virus; dendritic cells; virus vectors; cell; virus
Prior art date: 1998-07-31

Application number

AT99936848T

Other languages

English (en)

Inventor

Robert Stuart Coffin

Benjamin Chain

Original Assignee

Biovex Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-31

Filing date

1999-08-02

Publication date

2007-10-15

1999-08-02 Application filed by Biovex Ltd filed Critical Biovex Ltd

2007-10-15 Application granted granted Critical

2007-10-15 Publication of ATE374829T1 publication Critical patent/ATE374829T1/de

Links

241001529453 unidentified herpesvirus Species 0.000 title abstract 3
239000013598 vector Substances 0.000 title 1
230000002238 attenuated effect Effects 0.000 abstract 2
210000004443 dendritic cell Anatomy 0.000 abstract 2
241000700605 Viruses Species 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001024 immunotherapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT99936848T 1998-07-31 1999-08-02 Herpesvirusvektoren für dendritische zellen ATE374829T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9816781.0A GB9816781D0 (en)	1998-07-31	1998-07-31	Herpes virus vectors for dendritic cells

Publications (1)

Publication Number	Publication Date
ATE374829T1 true ATE374829T1 (de)	2007-10-15

Family

ID=10836553

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99936848T ATE374829T1 (de)	1998-07-31	1999-08-02	Herpesvirusvektoren für dendritische zellen

Country Status (18)

Country	Link
US (2)	US6641817B1 (de)
EP (1)	EP1100942B1 (de)
JP (1)	JP4430824B2 (de)
KR (1)	KR100635246B1 (de)
CN (1)	CN1384884B (de)
AT (1)	ATE374829T1 (de)
AU (1)	AU765105B2 (de)
BR (1)	BR9912653A (de)
CA (1)	CA2337494C (de)
CY (1)	CY1107844T1 (de)
DE (1)	DE69937239T2 (de)
DK (1)	DK1100942T3 (de)
ES (1)	ES2294848T3 (de)
GB (2)	GB9816781D0 (de)
HK (1)	HK1037925A1 (de)
IL (1)	IL141126A0 (de)
PT (1)	PT1100942E (de)
WO (1)	WO2000008191A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3456099A (en)	1998-03-31	1999-10-18	Geron Corporation	Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en)	1998-03-31	2008-07-22	Geron Corporation	Method for identifying and killing cancer cells
GB9816781D0 (en) *	1998-07-31	1998-09-30	Univ London	Herpes virus vectors for dendritic cells
GB0009079D0 (en) *	2000-04-12	2000-05-31	Neurovex Ltd	Herpes viruses for immune modulation
US6713067B2 (en)	1998-07-31	2004-03-30	Biovex Limited	Herpes viruses for immune modulation
US7030228B1 (en)	1999-11-15	2006-04-18	Miltenyi Biotec Gmbh	Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001053505A2 (en)	2000-01-21	2001-07-26	Biovex Limited	Herpes virus strains for gene therapy
US7063851B2 (en)	2000-04-12	2006-06-20	Biovex Limited	Herpes viruses for immune modulation
EP1406668A1 (de) *	2001-05-02	2004-04-14	Ramot at Tel-Aviv University Ltd.	Zusammengesetzte onkolytische herpesvirusvektoren
EP2213300B1 (de) *	2001-05-09	2015-03-25	Takara Bio, Inc.	Zusammensetzung und Verfahren zur Behandlung von krebs mittels Herpesviren
GB0203285D0 (en) *	2002-02-12	2002-03-27	Brown Susanne M	An herpes simplex virus complex
JP2004099584A (ja)	2002-05-02	2004-04-02	Keio Gijuku	Ｈｓｖを用いた抗腫瘍剤
US8216564B2 (en)	2002-05-02	2012-07-10	Ramot At Tel-Aviv University Ltd.	Composite oncolytic herpes virus vectors
CA2421269A1 (en)	2002-08-09	2004-02-09	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7977049B2 (en)	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) *	2003-07-25	2003-08-27	Biovex Ltd	Viral vectors
US20100008944A1 (en) *	2005-07-29	2010-01-14	President And Fellows Of Harvard College	Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) *	2007-04-09	2009-01-14	인제대학교 산학협력단	이종 유전자 발현을 위한 숙주균 및 그의 이용방법
US9181315B2 (en)	2009-01-08	2015-11-10	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
JP6342115B2 (ja)	2009-03-20	2018-06-13	メゾブラスト，インコーポレーテッド	再プログラム化多能性細胞の作製
CA2787628A1 (en)	2010-01-21	2011-07-28	Dana-Farber Cancer Institute, Inc.	Context specific genetic screen platform to aid in gene discovery and target validation
WO2012064743A2 (en)	2010-11-08	2012-05-18	The Johns Hopkins University	Methods for improving heart function
US8969519B2 (en)	2011-09-13	2015-03-03	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (en)	2011-10-14	2013-04-18	Dana-Farber Cancer Institute, Inc.	Znf365/zfp365 biomarker predictive of anti-cancer response
EP3134546A4 (de)	2014-04-24	2017-12-06	Dana-Farber Cancer Institute, Inc.	Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
CA2963091A1 (en)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6941561B2 (ja)	2014-10-09	2021-09-29	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
AU2016229238B2 (en)	2015-03-06	2022-06-02	Dana-Farber Cancer Institute, Inc.	PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
CN105219738A (zh) *	2015-09-21	2016-01-06	北京神源德生物科技有限公司	重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219739A (zh) *	2015-09-21	2016-01-06	北京神源德生物科技有限公司	重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CA3002676A1 (en)	2015-10-29	2017-05-04	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CA3018332A1 (en)	2016-03-21	2017-09-28	Dana-Farber Cancer Institute, Inc.	T-cell exhaustion state-specific gene expression regulators and uses thereof
AU2017332721B2 (en)	2016-09-20	2023-11-09	Sara BUHRLAGE	Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
US11820822B2 (en)	2017-06-06	2023-11-21	Dana-Farber Cancer Institute, Inc.	Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
CA3091960A1 (en)	2018-03-19	2019-09-26	Boehringer Ingelheim Vetmedica Gmbh	New ehv insertion site ul43
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP4343004A2 (de)	2020-10-19	2024-03-27	Dana-Farber Cancer Institute, Inc.	Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
US20240024474A1 (en)	2020-11-13	2024-01-25	David Avigan	Personalized fusion cell vaccines
EP4288140A1 (de)	2021-02-05	2023-12-13	Iovance Biotherapeutics, Inc.	Adjuvante therapie für krebs
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
WO2023158732A1 (en)	2022-02-16	2023-08-24	Dana-Farber Cancer Institute, Inc.	Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2141574C (en) *	1992-07-31	2009-11-24	David Knipe	Herpesvirus vaccines
GB9615794D0 (en)	1996-07-26	1996-09-04	Medical Res Council	Mutant herpes simplex virus strains and uses thereof
US5998174A (en) *	1997-05-12	1999-12-07	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Multigene vectors
US6713067B2 (en) *	1998-07-31	2004-03-30	Biovex Limited	Herpes viruses for immune modulation
GB9816781D0 (en) *	1998-07-31	1998-09-30	Univ London	Herpes virus vectors for dendritic cells
US7063851B2 (en) *	2000-04-12	2006-06-20	Biovex Limited	Herpes viruses for immune modulation

1998
- 1998-07-31 GB GBGB9816781.0A patent/GB9816781D0/en not_active Ceased
1999
- 1999-08-02 CN CN99811376XA patent/CN1384884B/zh not_active Expired - Lifetime
- 1999-08-02 US US09/744,942 patent/US6641817B1/en not_active Expired - Lifetime
- 1999-08-02 DE DE69937239T patent/DE69937239T2/de not_active Expired - Lifetime
- 1999-08-02 DK DK99936848T patent/DK1100942T3/da active
- 1999-08-02 AU AU51822/99A patent/AU765105B2/en not_active Expired
- 1999-08-02 CA CA002337494A patent/CA2337494C/en not_active Expired - Lifetime
- 1999-08-02 BR BR9912653-2A patent/BR9912653A/pt not_active IP Right Cessation
- 1999-08-02 AT AT99936848T patent/ATE374829T1/de active
- 1999-08-02 JP JP2000563814A patent/JP4430824B2/ja not_active Expired - Lifetime
- 1999-08-02 WO PCT/GB1999/002529 patent/WO2000008191A2/en active IP Right Grant
- 1999-08-02 KR KR1020017001361A patent/KR100635246B1/ko not_active IP Right Cessation
- 1999-08-02 PT PT99936848T patent/PT1100942E/pt unknown
- 1999-08-02 IL IL14112699A patent/IL141126A0/xx not_active IP Right Cessation
- 1999-08-02 GB GB0104400A patent/GB2361921B/en not_active Expired - Lifetime
- 1999-08-02 ES ES99936848T patent/ES2294848T3/es not_active Expired - Lifetime
- 1999-08-02 EP EP99936848A patent/EP1100942B1/de not_active Expired - Lifetime
2001
- 2001-11-21 HK HK01108180A patent/HK1037925A1/xx not_active IP Right Cessation
2005
- 2005-06-20 US US11/155,688 patent/US20050249707A1/en not_active Abandoned
2007
- 2007-12-27 CY CY20071101634T patent/CY1107844T1/el unknown

Also Published As

Publication number	Publication date
EP1100942A2 (de)	2001-05-23
GB0104400D0 (en)	2001-04-11
EP1100942B1 (de)	2007-10-03
KR100635246B1 (ko)	2006-10-19
AU765105B2 (en)	2003-09-11
PT1100942E (pt)	2007-12-06
CN1384884B (zh)	2010-12-08
BR9912653A (pt)	2001-05-02
IL141126A0 (en)	2002-02-10
DE69937239T2 (de)	2008-07-24
DE69937239D1 (de)	2007-11-15
GB2361921B (en)	2003-12-17
CA2337494A1 (en)	2000-02-17
AU5182299A (en)	2000-02-28
CY1107844T1 (el)	2013-06-19
JP2003502008A (ja)	2003-01-21
GB9816781D0 (en)	1998-09-30
WO2000008191A3 (en)	2000-06-08
US20050249707A1 (en)	2005-11-10
HK1037925A1 (en)	2002-02-22
KR20010072162A (ko)	2001-07-31
ES2294848T3 (es)	2008-04-01
JP4430824B2 (ja)	2010-03-10
CA2337494C (en)	2009-06-23
WO2000008191A2 (en)	2000-02-17
GB2361921A (en)	2001-11-07
CN1384884A (zh)	2002-12-11
US6641817B1 (en)	2003-11-04
DK1100942T3 (da)	2008-02-04

Legal Events

Date

Code

Title

Description

2008-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1100942

Country of ref document: EP

Publication	Publication Date	Title
ATE374829T1 (de)	2007-10-15	Herpesvirusvektoren für dendritische zellen
ATE224442T1 (de)	2002-10-15	Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
SI1573465T1 (sl)	2008-08-31	Postopek in sistem za hevristično zaznavanje virusov v izvršni kodi
DK0918848T3 (da)	2007-04-10	Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
CY1106785T1 (el)	2012-05-23	Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
DE60037428D1 (de)	2008-01-24	Ionenmobilitäts-spektrometer
ATE466932T1 (de)	2010-05-15	Vermehrung von viren in zellkultur
BR0207775A (pt)	2004-03-30	Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
BR9815761A (pt)	2000-12-26	Processo a vácuo para a fabricação de copolìmeros de siloxano-oxialquileno
CY1105439T1 (el)	2010-04-28	Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
TR199900656T2 (xx)	1999-08-23	�ndanonlar ile 262 ve 20S proteazomun engellenmesi.
SE9604581D0 (sv)	1996-12-12	An agent against cancer and virus infections
EP1356076A4 (de)	2004-03-17	Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
OA09653A (en)	1993-05-15	Rubella peptides
RU2003108334A (ru)	2004-09-10	Микроскоп с термолинзой
DK1044377T3 (da)	2007-11-19	Fremgangsmåde til påvisning af Borna disease virus (BDV)-infektioner
Chen	2005	The almost lattice isometric copies of $ c_0 $ in Banach lattices
NO20005321L (no)	2000-12-20	Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
Ambroladze et al.	1996	Research Problems
EP1091753A4 (de)	2004-11-17	Antiproliferative und antivirale proteine und peptide
EA200500071A1 (ru)	2005-08-25	Способ повышения экспрессии опухолевого антигена с применением тималфазина
TH84976A (th)	2007-06-04	วิธีการวินิจฉัยการติดเชื้อด้วยโคโรนาไวรัส ต้นเหตุของโรคซาส์ (sars)
TH84976B (th)	2007-06-04	วิธีการวินิจฉัยการติดเชื้อด้วยโคโรนาไวรัส ต้นเหตุของโรคซาส์ (sars)
RU93026038A (ru)	1996-06-10	Способ дифференциации вакцинных и эпизоотических штаммов днк и рнк-содержащих вирусов
ATE290209T1 (de)	2005-03-15	Assay für antivirusmittel